Dayvigo Pediatric (Under 12) Transition to Adult Care

Why the Pediatric-to-Adult Transition Matters for Lemborexant

Transitioning a patient from pediatric to adult care while they are on lemborexant requires more than a change of provider. The FDA has not approved lemborexant for anyone under 18, and any use in a child under 12 is off-label and carries meaningful regulatory, pharmacokinetic, and developmental considerations that must be formally re-evaluated when adult prescribing begins.

The transition window is not a handshake. It is a clinical reassessment of whether the drug is still the right choice, whether the dose that worked in a lighter, developing body is appropriate for an adult frame, and whether the underlying sleep disorder diagnosis still fits.

The Regulatory Baseline: No Approved Pediatric Indication

The FDA approved lemborexant in December 2019 for adult insomnia disorder at 5 mg and 10 mg nightly doses. The approval was based on two key trials, SUNRISE-1 and SUNRISE-2, which enrolled adults aged 18 and older exclusively. SUNRISE-2 (N=949) demonstrated statistically significant improvements in subjective sleep onset latency and wake after sleep onset versus placebo at both doses over six months, with a p-value <0.001 for the primary endpoints at week 1 and month 6 [1].

No pediatric efficacy or safety data from controlled trials in children under 12 existed at the time of original approval. The FDA prescribing information includes no dosing guidance for pediatric patients, and the drug carries a standard adult-only label [2].

Off-Label Use in Children Under 12: Why It Happens

Despite no formal approval, orexin receptor antagonists are sometimes considered in children with neurodevelopmental disorders such as autism spectrum disorder (ASD) or Smith-Magenis syndrome, conditions where melatonin and behavioral interventions have failed. A 2022 review in the Journal of Child Neurology documented off-label hypnotic prescribing patterns in pediatric neurology practices, noting that clinicians often face a gap between clinical need and approved therapies [3].

Lemborexant has a pharmacologic mechanism that is appealing in some pediatric contexts. It does not cause next-morning sedation at the same rate as benzodiazepines and does not carry the dependence scheduling of traditional sedative-hypnotics. Still, the absence of pediatric PK data means clinicians are extrapolating adult parameters onto a population with different hepatic enzyme activity, body fat distribution, and CNS maturation.

Pharmacokinetic Differences That Drive Transition Risk

In adults, lemborexant reaches peak plasma concentration (Tmax) in approximately 1 to 3 hours and has a mean elimination half-life of 17 to 19 hours. It is metabolized primarily by CYP3A4. In pediatric patients, CYP3A4 activity is variable and maturational changes in hepatic enzyme expression continue through adolescence and into early adulthood [4].

A child who tolerated 5 mg nightly at age 10 may have substantially different drug exposure at age 15 due to body weight changes and enzyme maturation. By age 18 to 19, CYP3A4 activity typically reaches adult steady-state levels. This means a dose established in childhood may produce higher or lower plasma concentrations than expected once adult hepatic function is fully established. The transition appointment is the right moment to recalculate exposure and consider a fresh titration if clinically warranted.

FDA Approval Status and the Off-Label Pediatric Context

Lemborexant holds a Schedule IV controlled substance classification under the DEA, which does not change at the transition point but does require new adult prescribing documentation. The adult provider must issue a new prescription under their own DEA registration; the pediatric provider's prescription does not carry forward automatically in most state pharmacy systems.

SUNRISE Trial Data and Why It Does Not Generalize to Children

SUNRISE-1 (N=291) was a 30-night polysomnographic study comparing lemborexant 5 mg and 10 mg against placebo and zolpidem tartrate extended-release 6.25 mg. The primary endpoint was latency to persistent sleep (LPS) by PSG. Lemborexant 10 mg reduced LPS by a mean of 23.2 minutes from baseline versus 12.8 minutes for placebo at night 30 [1]. SUNRISE-1 enrolled adults aged 18 to 88, with no pediatric arm.

Extrapolating these PSG findings to a prepubertal child is not straightforward. Sleep architecture in children under 12 contains substantially more slow-wave sleep (N3) and different REM cycling patterns than adult sleep. An intervention that improves LPS in an adult may affect pediatric sleep architecture differently, potentially suppressing restorative stages whose role in neurodevelopment is significant [5].

Ongoing Pediatric Research

Eisai, the drug's manufacturer, has initiated studies examining lemborexant in pediatric populations with specific neurodevelopmental indications. ClinicalTrials.gov lists at least one Phase 3 study (NCT05559437) examining lemborexant in children and adolescents aged 2 to 17 with ASD-associated insomnia. Results from that study may change the regulatory field. Until an FDA supplemental approval is issued, however, adult care providers receiving transitioning patients should treat the drug as unapproved in that age group and require a full clinical re-evaluation before continuing the prescription [6].

The Transition Protocol: A Step-by-Step Clinical Framework

A well-structured transition from pediatric to adult sleep medicine care for a patient on lemborexant should include five discrete phases: pre-transition preparation, medical record transfer, clinical reassessment, prescription re-establishment, and long-term monitoring. Each phase has specific clinical tasks tied to the unique pharmacology of the drug.

Phase 1: Pre-Transition Preparation (12 to 18 Months Before Transfer)

The pediatric provider should begin the transition conversation no later than 12 months before the anticipated handoff. This window allows time to gather comprehensive records, ensure the receiving adult provider has specialty training in sleep medicine, and discuss with the patient and family what changes to expect.

Key preparation tasks include documenting the original insomnia diagnosis with supporting sleep logs or PSG data, listing all prior failed therapies, recording the current dose and any dose adjustments made during growth, and compiling adverse event history.

The American Academy of Sleep Medicine (AASM) does not publish a specific transition protocol for lemborexant, but its 2017 clinical practice guideline on pediatric behavioral insomnia notes that any pharmacologic intervention in children should be "periodically reassessed for continued necessity and appropriateness as the child develops" [7]. That principle applies directly here.

Phase 2: Medical Record Transfer and Pharmacist Briefing

The adult-care pharmacy team needs the full medication history. Lemborexant has 14 documented clinically significant drug interactions, predominantly CYP3A4 inducers (such as rifampin, which can reduce lemborexant AUC by up to 75%) and inhibitors (such as clarithromycin, which may double plasma exposure) [2]. A new provider unaware of a co-prescribed CYP3A4 modifier could inadvertently create a sub-therapeutic or toxic drug level.

A pharmacist-led medication reconciliation at the transition appointment reduces this risk. The Joint Commission's 2023 National Patient Safety Goal NPSG.03.06.01 requires medication reconciliation at all care transitions, and lemborexant's interaction profile makes this requirement especially relevant [8].

Phase 3: Clinical Reassessment by the Adult Provider

The adult sleep medicine provider should perform a full insomnia diagnostic workup at the first visit, not simply renew the existing prescription. This means:

• Administering validated adult insomnia tools such as the Insomnia Severity Index (ISI) or the Pittsburgh Sleep Quality Index (PSQI).
• Reviewing whether a comorbid condition driving the sleep disorder, such as ASD, ADHD, or anxiety, has been adequately treated and whether that treatment has changed since the original lemborexant prescription was written.
• Checking hepatic function. The FDA prescribing information states that lemborexant is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) and should be used with caution in moderate impairment [2]. Hepatic function should be formally evaluated at transition.

If the adult provider concludes that insomnia persists and lemborexant remains appropriate, they should prescribe de novo starting at 5 mg and titrating based on adult response, rather than assuming the pediatric dose was optimal.

Phase 4: Prescription Re-Establishment Under Adult Standards

A new prescription requires written informed consent from the patient as an adult, not a guardian. This is a procedural requirement that pediatric practices may overlook when preparing transition summaries. The adult patient must understand the Schedule IV status of the drug, the risk of next-morning impaired driving at the 10 mg dose (a labeled warning in the FDA prescribing information), and the absence of long-term safety data beyond 12 months in any population [2].

Patients who were prescribed lemborexant as minors under guardian consent have never personally signed a prescribing consent form. The transition visit is the first time the patient, as a legal adult, gives that consent independently.

Phase 5: Long-Term Monitoring in Adult Care

Adult sleep medicine follows differ from pediatric follow-up in cadence and focus. The pediatric provider may have monitored growth and neurodevelopmental milestones alongside sleep. The adult provider should monitor:

• Daytime function and performance, using objective tools when possible.
• CNS depressant co-prescriptions, which are more common in adults and multiply lemborexant's sedation risk.
• Emergence of obstructive sleep apnea, which becomes more prevalent after puberty and can confound insomnia diagnosis. The FDA label notes that lemborexant has not been studied in patients with severe OSA and may worsen respiratory function in susceptible individuals [2].
• Annual reassessment of continued need, as insomnia often responds to cognitive behavioral therapy for insomnia (CBT-I) without medication when properly delivered. A 2021 meta-analysis of CBT-I across 87 trials (N=6,928) found a mean reduction of 9.4 points on the ISI, which exceeds the minimally important clinical difference of 6 points [9].

Safety Profile: What Changes at the Adult Transition

The labeled adult safety profile of lemborexant is the first real pharmacovigilance reference point for any transitioning patient, because no formal pediatric safety database exists for this drug.

CNS Depression and Next-Morning Impairment

The FDA prescribing information includes a boxed-level warning-equivalent note (though not a black box) about next-morning impairment. In SUNRISE-2, driving simulation performance was significantly impaired at 9 hours post-dose at the 10 mg dose in a subset of adult patients [2]. Any adult patient on lemborexant 10 mg must be counseled not to drive or operate heavy machinery until they know how the drug affects them at their specific dose.

For a teenager transitioning to adult care who may be newly licensed to drive, this counseling point is especially time-sensitive. The prescribing clinician should document this discussion in the transition note.

Sleep Paralysis, Hypnagogic Hallucinations, and Cataplexy-Like Events

As a dual orexin receptor antagonist, lemborexant blocks the wake-promoting neuropeptides orexin-A and orexin-B. In rare cases, orexin suppression can produce REM-intrusion events including sleep paralysis and hypnagogic hallucinations. The SUNRISE-2 trial reported sleep paralysis in 2% of lemborexant 10 mg users versus 0.2% placebo [1]. Adolescents and young adults have higher baseline rates of isolated sleep paralysis than older adults, which may increase the apparent incidence of this adverse effect in the transition age group [10].

Drug Abuse Potential

Schedule IV classification reflects a recognized, if low, abuse potential. The DEA classifies lemborexant alongside other sedative-hypnotics including zolpidem and eszopiclone. A young adult transitioning into college environments or other high-stress settings should be counseled specifically about the risks of dose escalation without medical supervision and co-use with alcohol, which increases CNS depression in an additive fashion.

Communicating with Families During the Transition

Families of patients who were managed for insomnia throughout childhood often have strong feelings about the medications that helped their child sleep. The transition conversation must include both the patient and the parent or caregiver, with clarity about whose consent and whose medical decisions take precedence once the patient is 18.

A useful clinical principle from the Society for Adolescent Health and Medicine (SAHM) 2020 position statement on transition care is that "the young adult should be the primary communicant with the care team by age 18, with family involvement only as the patient directs" [11]. Applying this to lemborexant prescribing means the adult provider discusses the drug's risks, consent, and dosing directly with the young adult patient, not primarily with parents.

This shift can feel abrupt to families accustomed to guardian-centered pediatric care. Explaining it explicitly and early (at the 12-month pre-transition appointment) reduces friction at the actual handoff visit.

Special Populations Within the Pediatric Transition Group

Neurodevelopmental Disorders

Patients with ASD or other neurodevelopmental disorders who used lemborexant off-label as children may have limited capacity for self-report of adverse effects. The adult provider should assess communication capacity and ensure that a caregiver or supported decision-making partner can report side effects accurately.

The ongoing Phase 3 trial NCT05559437 is specifically studying lemborexant in children and adolescents with ASD-associated insomnia and may provide the first controlled safety data in this population. If trial results are published before the patient's transition, the adult provider should review them before re-prescribing [6].

Smith-Magenis Syndrome and Inverted Melatonin Rhythm

Smith-Magenis syndrome (SMS) causes an inverted circadian melatonin secretion pattern, producing daytime sleepiness and nighttime wakefulness. Some SMS patients have been prescribed orexin antagonists off-label to manage the nighttime arousal component. As these patients age into adulthood, the adult provider must understand that the standard insomnia framing may not apply; what looks like insomnia is a circadian misalignment disorder that may respond differently to lemborexant than primary insomnia does.

The Endocrine Society's 2015 clinical practice guideline on melatonin and circadian disorders provides guidance on circadian phenotyping that can help the adult provider distinguish primary insomnia from circadian rhythm sleep-wake disorder before continuing or modifying lemborexant therapy [12].

Documentation and Legal Considerations

The transition from pediatric to adult care creates a documentation gap that can expose both providers to liability. The pediatric provider should issue a formal transition summary that includes: the original diagnosis and date, all prior pharmacotherapy including doses and durations, adverse effects experienced, reason lemborexant was selected over alternatives, and any off-label use acknowledgment signed by the guardian at the time of prescribing.

The adult provider should document that they received this summary, conducted an independent reassessment, obtained adult patient consent, and made an independent prescribing decision. This documentation chain is particularly relevant for a Schedule IV drug prescribed to a patient who is new to the adult prescriber and was previously managed under off-label pediatric protocols.